Bluejay Diagnostics, Inc. (BJDX)

NCM – Цена в реальном времени. Валюта: USD

1.79

+0.03 (1.70%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.82

+0.01 (0.42%)

До открытия: May 13, 2026, 4:43 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Bluejay Diagnostics, Inc. (BJDX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Видео

No Data

Пресс-релизы

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Search stocks

Bluejay Diagnostics, Inc. (BJDX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Видео

No Data

Пресс-релизы

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics